-- 1 of 25 -- nd July 16, 2025 -- 2 of 25 -- Cautionary note on Forward-looking statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary note on Non-GAAP financial measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website. 3 -- 3 of 25 -- REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology; JNJ-2113 was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize for a broad range of indications Immunology INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Neuroscience PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S. Department of Health and Human Services (HHS) Infectious Diseases INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx Cardiovascular/ Metabolism/Other IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited; AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab A/S; LAZCLUZE licensed from Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc. relates to several antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc. Oncology UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Pulmonary Hypertension Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C. Global Public Health Strategic partnerships, collaborations & licensing arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: 4 -- 4 of 25 -- CEO Remarks Sales performance and earnings review Cash position and guidance update Q&A Agenda 5 John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Darren Snellgrove Vice President, Investor Relations Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, MedTech 1 2 3 4 -- 5 of 25 -- Joaquin Duato Chairman and Chief Executive Officer -- 6 of 25 -- 7 Q2 Earnings Summary 1,2 operational sales growth Innovative Medicine MedTech Strong momentum in Cardiovascular, Surgery and Vision 3.8%1,3 operational sales growth $15 billion+ in quarterly sales for first time 13 brands growing double digits 6.1%1 operational sales growth 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes an approximate (710) basis point headwind from STELARA 3 Includes an approximate (1,170) basis point headwind from STELARA -- 7 of 25 -- Innovative Medicine 8 10+ products in market 26 approved indications 6 products in market 14 approved indications 5 products in market 6 approved indications Oncology Neuroscience Innovative Medicines: Innovative Medicines: Innovative Medicines: Immunology -- 8 of 25 -- MedTech 9 Addressing one of the largest unmet needs in healthcare Advancing the science of surgery and pioneering what's next Developing transformational innovations to improve the health of patients’ eyes Cardiovascular Surgery Vision MedTech Innovation: MedTech Innovation: MedTech Innovation: VARIPULSE Platform Dual Energy THERMOCOOL SMARTTOUCH SF Catheter Shockwave Intravascular Lithotripsy System OMNYPULSE Catheter OTTAVA Robotic Surgical System ETHICON 4000 Surgical Stapler ACUVUE® OASYS 1-Day Family TECNIS Odyssey TECNIS PureSee Impella® Heart Pump Technology -- 9 of 25 -- -- 10 of 25 -- Darren Snellgrove Vice President, Investor Relations -- 11 of 25 -- % Change Q2 2024 Q2 2025 Regional sales results Operational1 Reported 7.8% 7.8% $12.6 $13.5 U.S. (1.9) 3.3 5.2 5.4 Europe 6.2 (0.5) 1.2 1.2 Western Hemisphere (ex U.S.) 2.4 4.4 3.5 3.6 Asia-Pacific, Africa 0.6 3.2 9.9 10.2 International 4.6% 5.8% $22.4 $23.7 Worldwide (WW) Dollars in billions 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 2nd Quarter 2025 sales 12 -- 12 of 25 -- $23.7 $22.4 $6.7 $6.8 (1.8)%; (3.9)%1 $2.77 $2.82 Dollars in billions, except EPS Reported %; Operational %1 Sales Adjusted earnings2 Adjusted EPS2 5.8%; 4.6%1 GAAP earnings $5.5 $4.7 (2.1)% Q2 2025 Q2 2024 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 2nd Quarter 2025 financial highlights GAAP EPS 13 Q2 2025 Q2 2024 Q2 2025 Q2 2024 Q2 2025 Q2 2024 Q2 2025 Q2 2024 $2.29 $1.93 18.2% 18.7% -- 13 of 25 -- Immunology $3,993 Infectious Diseases $803 Neuroscience $2,051 Oncology $6,312 CVM/Other $930 PH $1,113 ■ Reported growth ■ Operational growth1 $15,202 4.9%, 3.8% WW sales $MM Key drivers of operational performance1 • DARZALEX increase driven by continued strong share gains and market growth • ERLEADA increase driven by continued share gains and market growth, partially offset by the impact of Part D redesign • CARVYKTI increase driven by continued share gains and capacity expansion • TECVAYLI and TALVEY growth driven by ongoing launches • RYBREVANT/LAZCLUZE growth driven by ongoing launch • Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA due to competitive pressures and the impact of Part D redesign Oncology • TREMFYA increase due to share gains, market growth, and launch-related inventory dynamics, partially offset by the impact of Part D redesign • SIMPONI/SIMPONI ARIA growth driven mainly by MSD3 return of rights in Europe • REMICADE increase due to favorable patient mix, market growth, and MSD3 return of rights in Europe, partially offset by biosimilar competition • STELARA decline driven by the impact of biosimilar competition and Part D redesign Immunology • SPRAVATO growth driven by continued increased physician and patient demand • CAPLYTA acquired April 2, 2025 • INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA decline primarily driven by the impact of Part D redesign and unfavorable patient mix Neuroscience • OPSUMIT/OPSYNVI increase driven by market growth, inventory dynamics, and share gains, partially offset by the impact of Part D redesign • UPTRAVI increase driven by market growth and inventory dynamics partially offset by the impact of Part D redesign Pulmonary Hypertension (PH) • Declines across the portfolio including COVID-19 Vaccine, partially offset by EDURANT growth Infectious Diseases • XARELTO growth driven by the impact of Part D redesign and market growth partially offset with continued share declines Cardiovascular / Metabolism / Other (CVM/Other) Adjusted operational sales2: WW: 2.4%, U.S. 5.2%, Int’l (1.6)% Innovative Medicine highlights – 2nd quarter 2025 WW 4.9%, U.S. 7.6%, Int’l 1.0% Reported: WW 3.8%, U.S. 7.6%, Int’l (1.6)% Operational1: 4.2%, 4.0% 7.1%, 6.2% 24.0%, 22.3% (16.8)%, (19.0)% (15.4)%, (16.0)% Strong operational growth1 of 3.8% driven primarily by Oncology and Neuroscience 15.1%, 14.4% 14 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 3 MSD: Merck, Sharp, & Dohme 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded Stelara impacted results1 by ~(1,170) basis points -- 14 of 25 -- Key drivers of operational performance1 • Electrophysiology: Growth driven by strength in competitive mapping, new product performance (VARIPULSE, TRUPLUSE, NUVISION, QDOT), procedure growth, and lapping of prior year inventory dynamics in China, partially offset by competitive pressures in PFA • Abiomed: Double digit growth driven by continued strong adoption of Impella 5.5 and Impella CP • Shockwave: Acquired May 31, 2024 Cardiovascular • Hips: Reflects impacts of volume-based procurement (VBP) in China, revenue disruption from the previously announced Orthopaedics transformation, and trade inventory dynamics, partially offset by procedure growth • Trauma: Primarily driven by lapping of strong prior year comparator offset by recently launched products, procedure growth, and commercial execution • Knees: Driven by competitive pressures, market headwinds, and revenue disruption from the previously announced Orthopaedics transformation, partially offset by strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solutions • Spine, Sports & Other: Reflects competitive pressures, price pressures in the U.S. Early Interventional segment, revenue disruption from the previously announced Orthopaedics transformation, and VBP in China • Spine: ~ -7% WW, ~ -4% U.S., ~ -12% Int’l Orthopaedics • Advanced • Biosurgery: ~ +7% Growth driven by continued strength of the portfolio (SURGIFLO, SURGICEL Powder, Evarrest, and VISTASEAL) and commercial execution, partially offset by VBP in China • Endocutters: ~ +1% Increase primarily due to strategic price actions partially offset by VBP in China and competitive pressures • Energy: ~ -6% Due to competitive pressures, Harmonic market decline in the U.S., VBP in China and OUS tender timing, partially offset by go-to-market changes in EMEA • General: Growth primarily due to technology penetration and upgrades within our differentiated Wound Closure portfolio (Barbed & PLUS Sutures) Surgery • Contact Lenses/Other: Growth driven by price actions and continued strong performance of the ACUVUE OASYS 1-Day family (recent launch of OASYS MAX 1-Day including MAX 1-day multifocal for Astigmatism) • Surgical: Increase reflects continued strength of recent innovation (TECNIS Odyssey, TECNIS PureSee, TECNIS Eyhance) and commercial execution Vision Adjusted operational sales2: WW 4.1%, U.S. 4.7%, Int’l 3.4% Orthopaedics $2,305 Surgery $2,555 Vision $1,369 Cardiovascular $2,313 ■ Reported growth ■ Operational growth1 $8,541 7.3%, 6.1% WW sales $MM Strong operational growth1 of 6.1% due to Cardiovascular, commercial execution, and innovation WW 7.3%, U.S. 8.0%, Int’l 6.7% Reported: WW 6.1%, U.S. 8.0%, Int’l 4.1% Operational1: 23.5%, 22.3% 6.5%, 4.6% (0.3)%, (1.6)% 2.7%, 1.8% MedTech highlights – 2nd quarter 2025 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 15 -- 15 of 25 -- % Increase (Decrease) 2024 2025 % to Sales Amount % to Sales Amount 5.8 100.0 $22,447 100.0 $23,743 Sales to customers 11.0 30.6 6,869 32.1 7,628 Cost of products sold 3.4 69.4 15,578 67.9 16,115 Gross Profit 3.7 25.3 5,681 24.8 5,889 Selling, marketing and administrative expenses 2.2 15.3 3,440 14.8 3,516 Research and development expense 0.9 194 - - In-process research and development impairments (0.6) (125) 0.2 48 Interest (income) expense, net 2.9 653 0.5 107 Other (income) expense, net 0.0 (13) 0.3 64 Restructuring 12.9 25.6 5,748 27.3 6,491 Earnings before provision for taxes on income (10.2) 4.7 1,062 4.0 954 Provision for taxes on income 18.2 20.9 $4,686 23.3 $5,537 Net Earnings - 18.7 $1.93 $2.29 Net earnings per share (Diluted) 2,422.0 2,419.1 Average shares outstanding (Diluted) 18.5% 14.7% Effective tax rate . Adjusted earnings before provision for taxes and net earnings1 (2.6) 37.4 $8,404 34.5 $8,188 Earnings before provision for taxes on income (2.1) 30.5 $6,840 28.2 $6,699 Net earnings (1.8) $2.82 $2.77 Net earnings per share (Diluted) 18.6% 18.2% Effective tax rate 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website (Unaudited; Dollar and shares in millions except per share figures) 16 2nd Quarter 2025 Condensed consolidated statement of earnings -- 16 of 25 -- % Increase (Decrease) 2024 2025 Innovative Medicine % to Sales Amount % to Sales Amount 4.9 100.0 $14,490 100.0 $15,202 Sales to customers 9.5 20.0 2,905 20.9 3,180 Cost of products sold 3.8 80.0 $11,585 79.1 $12,022 Gross Profit 4.7 18.4 2,665 18.3 2,789 Selling, marketing and administrative expenses 5.8 18.7 2,712 18.9 2,869 Research and development expense (1.7) (254) (0.8) (129) Other segment items 1 0.5 44.6 $6,462 42.7 $6,493 Adjusted segment income before tax 2 1 Other segment items for each reportable segment include charges related to other income and expense 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the company's website (Unaudited; Dollar in millions) Adjusted earnings before provision for taxes on income by segment 17 % Increase (Decrease) 2024 2025 MedTech % to Sales Amount % to Sales Amount 7.3 100.0 $7,957 100.0 $8,541 Sales to customers 14.1 34.6 2,754 36.8 3,142 Cost of products sold 3.8 65.4 $5,203 63.2 $5,399 Gross Profit 7.4 33.5 2,666 33.4 2,862 Selling, marketing and administrative expenses 3.0 8.4 670 8.1 690 Research and development expense (2.2) (181) (0.6) (53) Other segment items 1 (7.2) 25.7 $2,048 22.2 $1,900 Adjusted segment income before tax 2 % Increase (Decrease) 2024 2025 Enterprise % to Sales Amount % to Sales Amount (2.6) 37.4 $8,404 34.5 $8,188 Adjusted segment income before tax 2 2nd Quarter 2025 -- 17 of 25 -- Joseph J. Wolk Executive Vice President, Chief Financial Officer -- 18 of 25 -- Capital allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases Higher priority Lower priority Investment in M&A Q2 2025 Dollars in billions $19 Cash and marketable securities ($51) Debt ($32) Net debt ~$6 Free cash flow1,2 Q2 2025: $3.5B invested in R&D $6.7B year-to-date $3.1B in dividends paid to shareholders; $6.1B year-to-date Note: Values may be rounded 1 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment 2 Estimated as of July 16, 2025. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings 3 Includes Intra-Cellular Therapies acquisition closed April 2, 2025 Note: Values may be rounded Capital allocation strategy 19 ~$15B3 deployed in strategic, inorganic growth opportunities -- 19 of 25 -- Increasing operational2 sales guidance to 4.8% and adjusted operational EPS2,4 to 7.0% (midpoints) Comments April 2025 July 2025 Increasing midpoint to 3.5% 2.0% - 3.0% 3.2% - 3.7% Adjusted operational sales1,2,6 Tightening range; Increasing midpoint by $0.9B to 4.8% $91.6B - $92.4B 3.3% - 4.3% $92.7B - $93.1B 4.5% - 5.0% Operational sales2,6 Tightening range; Increasing midpoint by $2.0B to 5.4% Incremental FX impact of $1.1B $91.0B - $91.8B 2.6% - 3.6% $93.2B - $93.6B 5.1% - 5.6% Estimated reported sales 3,6 Maintaining Increase of ~300 bps Increase of ~300 bps Adjusted pre-tax operating margin4,5 Maintaining $1.0 - $1.2 billion $1.0 - $1.2 billion Net other income4 Decreasing due to higher interest earned on cash balances $100 - $200 million $0 - $100 million Net interest expense / (income) Increasing due to an adjustment on global tax reserves 16.5% - 17.0% 17.0% - 17.5% Effective tax rate4 Tightening range; Increasing midpoint by $0.08 $10.50 - $10.70 5.2% - 7.2% $10.63 - $10.73 6.5% - 7.5% Adjusted EPS (operational)2,4 Tightening range; Increasing midpoint by $0.25 Incremental FX impact of $0.17 $10.50 - $10.70 5.2% - 7.2% $10.80 - $10.90 8.2% - 9.2% Adjusted EPS (reported)3,4 2025 P&L guidance 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Euro Average Rate: July 2025 = $1.13; Euro Spot Rate: July 2025 = $1.17 6 Excludes COVID-19 Vaccine Note: Values may be rounded 20 -- 20 of 25 -- Innovative Medicine • Expect more pronounced impact from newly launched products as the year progresses • STELARA biosimilar competition to accelerate; HUMIRA erosion curve remains the best proxy2 • Negative impact of Part D re-design, as a percent to sales, will be consistently applied throughout the year3 • Expect acceleration of newly launched products; full year impact of Shockwave acquisition • Lapping of prior year quarterly comparators to be considered • Normalized procedure volume and seasonality Phasing Considerations MedTech • One-time items impacting EPS last year: • Benefit of Kenvue dividend in the first two quarters • Higher interest income prior to Shockwave acquisition in May • Monetization of royalty rights in Q3 • IPR&D expense associated with NM-26 Bi-specific antibody acquisition (Q3) and V-Wave acquisition (Q4) P&L 21 Anticipate second half operational1 sales growth higher than the first half 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Once faced with material biosimilar competition, with the additive impact of Part D re-design 3 Products negatively impacted include STELARA, INVEGA long acting injectables, ERLEADA, OPSUMIT, UPTRAVI, TREMFYA and IMBRUVICA, partially offset by a favorable impact in XARELTO -- 21 of 25 -- Innovative Medicine Anticipated 2025 milestones1 driving long-term value creation MedTech 22 TAR-200 NMIBC RYBREVANT Sub-Q in NSCLC TREMFYA Sub-Q in UC CAPLYTA in aMDD icotrokinra in PsO and UC TREMFYA PsA RYBREVANT in HNC VOLT Plating System STSF Dual Energy OTTAVA IMPELLA ECP ATTUNE Revision Hinge ETHICON 4000 Stapler ACUVUE OASYS MAX for Astigmatism 1 List above is not inclusive of all 2025 anticipated milestones Sub-Q: Subcutaneous; NSCLC: Non-small cell lung cancer; UC: Ulcerative colitis; NMIBC: Non-muscle invasive bladder cancer; PsO: Psoriasis; HNC: head and neck cancer; aMDD: Adjunctive major depressive disorder; PsA: Psoriatic arthritis; STSF: SMARTTOUCH Surround Flow -- 22 of 25 -- Q&A John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Darren Snellgrove Vice President, Investor Relations Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, MedTech -- 23 of 25 -- Slide footer goes here if required 24 -- 24 of 25 -- POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA PRESENTATIONS¹ Phase III Phase I/ II US SIMPONI (golimumab) P US IMAAVY (nipocalimab ) US nipocalimab P US TAR-200 (RIS/gemcitabine plus cetrelimab) P AKEEGA (niraparib/abiraterone) P TAR-200 (RIS/gemcitabine plus cetrelimab) EU Pediatric Ulcerative Colitis (PURSUIT 2) EU Generalized Myasthenia Gravis (Vivacity MG3) Warm Autoimmune Hemolytic Anemia (ENERGY) Non Muscle Invasive Bladder Cancer (SunRISe-1) M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE) Non Muscle Invasive Bladder Cancer (SunRISe-1) STELARA (ustekinumab) P US SPRAVATO (esketamine) TREMFYA (guselkumab) P US AKEEGA (niraparib/abiraterone) P RYBREVANT / LAZCLUZE RYBREVANT (amivantamab) P EU Pediatric Crohn's Disease (UNITI JR) Treatment Resistant Depression monotherapy (TRD4005) P EU Ulcerative Colitis Subcutaneous Induction (ASTRO) P EU M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE) Non Small Cell Lung Cancer (MARIPOSA Final OS) Head and Neck Cancer (ORIGAMI-4) US TREMFYA (guselkumab) US CAPLYTA (lumateperone) US TREMFYA (guselkumab) P TREMFYA (guselkumab) P TALVEY + TECVAYLI Ulcerative Colitis Subcutaneous Induction (ASTRO) Adjunctive Treatment for Major Depressive Disorder Psoriatic Arthritis Structural Damage (APEX) Ulcerative Colitis Subcutaneous Induction (ASTRO) Multiple Myeloma Relapsed/Refractory (RedirecTT-1) P US TREMFYA (guselkumab) US DARZALEX (daratumumab) TREMFYA (guselkumab) P TREMFYA (guselkumab) P JNJ-4496 P EU Crohn's Disease Subcutaneous Induction (GRAVITI) EU Smoldering Multiple Myeloma (AQUILA) P EU Pediatric Psoriasis (PROTOSTAR) Psoriatic Arthritis Structural Damage (APEX) Hematological Malignancies (LYM1001) US TREMFYA (guselkumab) US DARZALEX (daratumumab) US STELARA (ustekinumab) P TREMFYA (guselkumab) P JNJ-5322 Pediatric Psoriasis (PROTOSTAR) P EU Frontline multiple myeloma transplant ineligible (CEPHEUS) EU Pediatric Ulcerative Colitis (UNIFI JR) Pediatric Psoriasis (PROTOSTAR) Multiple Myeloma (MMY1001) US TREMFYA (guselkumab) US TAR-200 (RIS/gemcitabine plus cetrelimab) P US STELARA (ustekinumab) P icotrokinra P RYBREVANT (amivantamab) Pediatric Juvenile Psoriatic Arthritis Non Muscle Invasive Bladder Cancer (SunRISe-1) Pediatric Crohn's Disease (UNITI JR) Psoriasis (ICONIC-LEAD) Colorectal Cancer (ORIGAMI-1 right- sided) P US TREMFYA (guselkumab) US RYBREVANT (amivantamab) US icotrokinra P icotrokinra P JNJ-8343 P EU Crohn's Disease (GALAXI) P EU Subcutaneous (PALOMA-3) EU Psoriasis (ICONIC) Psoriasis (ICONIC-TOTAL) Prostate Cancer (PCR1001) TREMFYA (guselkumab) IMBRUVICA (ibrutinib) icotrokinra JNJ-4804 Co-antibody Therapy P EU Ulcerative Colitis (QUASAR) EU Frontline MCL (Triangle) Psoriasis (ICONIC-Advance1/2) Psoriatic Arthritis (AFFINITY) P US IMAAVY (nipocalimab ) P aticaprant icotrokinra Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG) Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura 1) Ulcerative Colitis (ANTHEM) P RPGR Gene Therapy nipocalimab Combination Therapy Retinitis Pigmentosa (LUMEOS) Rheumatoid Arthritis (DAISY) Johnson & Johnson Innovative Medicine Pipeline Key Events in 2025* 1. In order to be on key events clinical presentation, data must be presented at a major medical meeting. *This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of July 16, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. 1 In order to be on key events clinical presentation, data must be presented at a major medical meeting. *This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investments. This information is as of July 16, 2025 to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information. = Achieved -- 25 of 25 --